Company intelligence / Profile preview

Skin2Neuron

Sydney, New South Wales, Australias2n.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Successfully reversed dementia-like syndrome in dogs with a natural form of Alzheimer's disease. Animal studies have shown significant improvement in memory functions, with treated dogs becoming "non-demented" within 3-6 months post-procedure. Histology data demonstrated the cells' ability to arrange themselves into functional neural networks that can supplant brain tissue degraded by disease.

Therapeutic areas: Neurology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

1 asset

HFN cell therapy (GABAergic)

Preclinical

Partnerships

Major global top 5 pharma partner (unnamed)

Beyond the preview

Go deeper on Skin2Neuron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skin2Neuron.

Explore the full profile